Volver al Inicio Volver al Inicio

Instituciones Pariticpantes:

CAMPAÑA DE ELIMINACIÓN DE LA RUBÉOLA Y EL SÍNDROME DE RUBÉOLA CONGÉNITA (SRC)

MÉXICO, 2008


"Si tienes entre 19 y 29 años y aún no te has vacunado, en MAYO, tienes una ÚLTIMA OPORTUNIDAD. Hazlo ahora, en tu centro de salud más cercano"

Selección Bibliográfica sobre Rubéola y Síndrome de Rubéola Congénita, Disponible en Texto Completo:

Publicaciones de la OMS:

  • Control of rubella and congenital rubella syndrome (CRS) in developing countries. Geneva: WHO, 2000. [Documento PDF: 107 KB]
  • Guidelines for surveillance of congenital rubella syndrome and rubella. Geneva: WHO, 1999. [Documento PDF: 120 KB]
  • Report of a meeting on preventing congenital rubella syndrome: immunization strategies, surveillance needs. Geneva: WHO, 2000 [Documento PDF: 326 KB]
  • WHO vaccine-preventable diseases: monitoring system 2006 global summaryGeneva: WHO, 2006 [Documento PDF: 4.79MB]
  • WHO technical workshop on the role of the laboratory detection of human papillomavirus in global disease revention and control [PDF: 641 KB]

Publicaciones de la OPS:

  • Boletín de Semanal de Sarampión / Rubéola [Link]
  • Guía de alertas para la sospecha de casos de síndrome de rubéola congénita: “Sospechando al sospechoso” [PDF: 607 KB]
  • Eliminación de la Rubéola y del Síndrome de Rubéola Congénita en las Américas. Informe sobre los progresos realizados. Comité Ejecutivo [PDF: 163 KB]
  • Estrategia Regional para Mantener los programas nacionales de vacunación en las Américas [PDF: 24 KB]
  • Expanded Program on Immunization in the Americas Volume XXVI, Number 1 February 2004 [PDF: 404 KB]
  • Mantenimiento de los Programas de Vacunación-Eliminación de la Rubéola y el Síndrome de Rubéola Congénita (SRC). Consejo Directivo [PDF: 66 KB]
  • Reunión Ad-hoc de Expertos para Establecer las Mejores Prácticas de Vigilancia del Síndrome de Rubéola Congénita [Link]
  • Rubella Watch [Link]
  • Rubéola Congénita. Incluye: Cuadros de Procedimientos, Manual AIEPI, Guía del Facilitador, [PDF: 593 KB]
  • Worldwide Distribution of Rubella Viruses, 1995-2005 [PDF: 193 KB]
  • XIII Meeting of the PAHO Technical Advisory Group of Vaccine Preventable Diseases. Conclusions and Recommendations. Final Report [PDF: 152 KB]

Para la lectura de documentos, es indispensable contar con Acrobat Reader

Nota: Si usted pertenece a alguna institución y/u organismo de salud,
solicite un disco interactivo con estas publicaciones en PDF al siguiente correo electrónico: cgc@mex.ops-oms.org
o envíe un oficio membretado a la siguiente dirección con sus datos para realizar el envío:
Av. Horacio No. 1855 (Esquina Periférico) Piso 3 - Oficina 305 Col. Polanco México D.F. C.P. 11510

Bibliografía Recomendada [Descargar el PDF aquí]

  • La rubéola y SRC
    • Gregg NM. Congenital cataract following German measles in the mother. Transactions of the Ophtalmological Society of Australia 1941;3:35-46.
    • Siegel M, Fuerst HT, Peress NS. Fetal mortality in maternal rubella: results of a prospective study from 1957 to 1964. Am J Obstetr Gynecol, 1966;96:247–53.
    • Giles JP, Cooper LZ, Krugman S. The Rubella Syndrome. J Pediatr. 1965;66:434-7
    • Cooper LZ. German measles. Sci Am. 1966;215:30-7.
    • Cooper LZ, Krugman S. Diagnosis and management: congenital rubella. Pediatrics. 1966;37:335-8
    • Sever JL, Hardy JB, Nelson KB, Gilkeson MR. Rubella in the Collaborative Perinatal Research Study. II. Clinical and laboratory findings in children through three years of age. Am J Dis Child 1969;118:123-32.
    • Ojala P, Vesikari T, Elo O. Rubella during pregnancy as a cause of congenital hearing loss. Am J Epidemiol, 1973; 98:395–401.
    • Dudgeon JA. Congenital Rubella. J Pediatrics 1975;6:1078-86.
    • Peckham CS. Clinical and laboratory study of children exposed in utero to maternal rubella. Arch Dis Child 1972;47:571-7.
    • Swartz TA. An extensive rubella epidemic in Israel, 1972: selected epidemiologic characteristics. Am J Epidemiol. 1976 103:60-6.
    • Cooper LZ. The history and medical consequences of rubella. Rev Infect Dis, 1985, 7 (suppl. 1): S2–S10.
    • Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 1982;9:781-4.
    • Grillner L, Forsgren M, Barr B, Boottiger M, Danielsson L, Verdier C. Outcome of Rubella during Pregnancy with Special Reference too the 17th – 24th Weeks of Gestation. Scand J Infect Dis 1983;15:321-5.
    • South MA and Sever JL. "Teratogen Update: The Congenital Rubella Syndrome. Teratology 1985; 31:297-307
    • Elango S, Reddy TNK, Shriwas SR. Ocular abnormalities in children from a Malaysian school for the deaf. Ann Trop Paediatr 1994, 14: 149–52.
    • Evans, AS & Kaslow, RA. Rubella. In: Viral Infections of Humans - Epidemiology and Control. 4th edition, New York USA, 1997:839-60.
    • Webster W. Teratogen Update: Congenital Rubella. Teratology, 1998; 58:13-23.
    • Remington JS, Klein JO (Ed). Infectious diseases of the fetus and newborn infant. Philadelphia, W.B. Saunders Company. Fifth Edition, 2001.
    • Banatvala JE, Brown DW. Rubella. Lancet 2004; 363:1127-37.
    • Cherry J., Feigin R. eds. Rubella. In: Textbook of Pediatric Infections Diseases 5th ed. Philadelphia, PA.: W B Saunders; 2004, Vol. 2, 2134-62
    • Yee Lee J, Bowden DS. Rubella Virus Replication and Links to Teratogenicity. Clin Microbiol Rev 2000; 13:571-87
    • Forrest JM, Turnbull FM, Sholler GF, et al. Gregg’s congenital rubella patients 60 years later. MJA 2002; 177:664-7

  • La vacuna contra la rubéola
    • Horstmann DM, Liebhaber H, Le Bouvier GL, Rosenberg DA, Halstead SB. Rubella: Reinfection of vaccinated and naturally immune persons exposed in an epidemic. N Engl J Med 1970; 283:771-8.
    • Batnavala JE, Druce A, Best JM, Al Nakib W. Specific IgM response after rubella vaccination; potencial application following inadvertent vaccination during pregnancy. Br Med J 1977;6097:1263-4.
    • Balfour HH, Groth KE, Edelman CK, Amren DP, Best JM, Banatvala JE. Rubella viraemia and antibody responses after rubella vaccination and reimmunization. Lancet 1981;1078-80.
    • Greaves WL, Orenstein WA, Hinman AR, Nersesian WS. Clinical efficacy of rubella vaccine. Pediatr Infect Dis J 1983;2:284-6.
    • Balfour HH, Groth KE, Edelman CK, RA27/3 rubella vaccine. Am J Dis Child 1990;134:350-3.
    • Centers for Disease Control and Prevention. Update on Adult Immunization Recommendation Practices Advisory Committee (ACIP). MMWR 1991;40(RR12):1-52.
    • Centers for Disease Control and Prevention. Measles, Mumps and Rubella - Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998;47(Nº RR-8):4-5.
    • Organización Mundial de la Salud, Departamento de Vacunas y Productos Biológicos. Supplementary Information on Vaccine Safety. Part 2: Background Rates of Adverse Events Following Immunization. Ginebra, 2000. Documento WHO/V&B/00.36.
    • Cruz-Rojo C, Rodríguez –Iglesias M, Olvera J, Álvarez-Girón M. Study of the immune response engendered by different combined measles, mumps and rubella (MMR) vaccines in an area of Andalusia (Spain). Vaccine 2003;22:280-6.
    • Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases (“The Pink Book”), 8th ed., Atlanta: CDC, 2004: 145-57.
    • Plotkin SA, Orenstein WA. Rubella Vaccine. In: Vaccines, Fourth Edition. Elsevier Inc. USA, 2004:707-43.

  • La epidemiología y la vigilancia
    • Jenifer Best, Castillo-Solorzano C, Spika JS, Icenogle J, Glasser J, Gay N, Andrus A, Arvin A. Reducing the Global burden of congenital rubella syndrome. Report of the WHO Steering Committee on Research Related to Measles and Rubella Vaccines and Vaccination, June 2004. Geneva Switzerland.
    • Centers for Disease Control and Prevention. Achievements in Public Health. Elimination of Rubella and Congenital Rubella Syndrome – United States, 1969-2004. MMWR 2005;54(March 21):1-4.
    • Horstmann DM, Riordan JT, Ohtawara M, Niederman JC. A Natural Epidemic of Rubella in a Closed Population: Virological and Epidemiological Observations. Arch Ges Virusforsch 1965;16:483-7.
    • Ulstrup J, Skaug JC, Stray-Pedersen B. A rubella epidemic in an unvaccinated pregnant population. 1: Screening methods and serological results. Scan J Infect Dis 1981;13:11-5.
    • Menser MA et al. Epidemiology of congenital rubella and results of rubella vaccination in Australia. Rev Infect Dis 1985;7(Suppl. 1):S37-S41.
    • Owens CS, Espino RT. Rubella in Panama: Still a problem Pediatr Infect Dis J 1989;8:110:5.
    • Sterh-Green PA, Cochi SL, Preblud SR, Orenstein WA. Evidence against increasing rubella seronegativity among adolescent girls. Am J Public Health 1990; 80:88
    • Mellinger AK, Cragan JD, Atkinson WL, Williams WW, Kleger B, Kimber RG, Tavris D. High incidence of congenital rubella syndrome after a rubella outbreak. Pediatr Infect Dis J 1995;14:573-8.
    • Cutts FT, Robertson SE, Díaz-Ortega JL y Samuel R. “Control of Rubella and Congenital Syndrome (CRS) in Developing Countries, Part 1: Burden of Disease from CRS.” Bulletin of the World Health Organization, 1997, 75: 55-68.
    • Cutts FT, Robertson SE, Samuel R y Díaz-Ortega JL. “Control of Rubella and congenital syndrome (CRS) in developing countries, Part 2: Vaccination Against Rubella.” Bulletin of the World Health Organization, 1997, 75: 69-80.
    • Schuler WW, Ref. S, Redd SC, Dykewicz CA. Changing Epidemiology of Congenital Rubella Syndrome in the United States. J Infect Dis 1998; 178:636-41.
    • Cutts FT. Guidelines for Surveillance of Congenital Rubella Syndrome and Rubella, Field Test Version. Ginebra: Organización Mundial de la Salud, 1999. Documento WHO/V&B/99.22.
    • Organización Panamericana de la Salud. La erradicación del sarampión: Guía práctica, Cuaderno técnico Nº 41. Washington, DC: OPS, 1999.
    • Panagiotopoulos T, Antoniadou I, Valassi-Adam E, y Berger A. Increase in Congenital Rubella Occurrence After Immunization in Greece: Retrospective Survey and Systematic Review. Br Med J, 1999; 319:1462-7.
    • Holmes SJ, Orenstein WA. Rubella. In: Viral Infections of Humans: Epidemiology and Control. Evans AS and Kaslow RA (Ed).. Plenum Publishing Corporation, United States of America. New York , 1997:839-60.
    • Plotkin, SA. Rubella Eradication. Vaccine, 2001;19: 3311-9.
    • Chin James. El control de las Enfermedades Infecciosas. Informe Oficial de la Asociación Estadounidense de Salud Pública. Organización Panamericana de la Salud. 17ª edición. Washington D.C.; 2001.
    • Reef SE, Frey TK, Theall K, Abernanthy E, Burnett CL, Icenogle J, Mason MccCauley M, Wharton M. The Changing Epidemiology of Rubella in the 1990s: On the Verge of Elimination and New Challenges for Control and Prevention. JAMA 2002;287:464-72.
    • Ávila-Agüero ML, Morice A, Castillo-Solórzano C, Soriano A, Valverde S, Ulloa-Gutiérrez R, Reef. S. Síndrome de rubéola congénita en Costa Rica: Importancia de la Vigilancia Activa. Anales Españoles Pediatría 2005;62:43-7.
    • Cooper LZ. Current lessons from 20th century serosurveillance data on rubella. Clin Infect Dis. 2001;33:1287
    • Reef S, Plotkin S, Cordero JF, Katz M, Cooper L, Schwartz B et al. Preparing for Elimination of Congenital Rubella Syndrome: Summary of a Workshop on CRS Elimination in the United States. Clin Infect Dis 2000;31:85-95.
    • Zimmerman L, Reef S. Incidence of Congenital Rubella Syndrome at a Hospital Serving a Predominantly Hispanic Populatio, El Paso, Texas. Pediatrics 2001; 107:1-4.

  • El laboratorio
    • Parkman PD, Buescher EL, Artenstein MS. Recovery o of rubella virus from army recruits. Proc Soc Exp Biol Med 1962;111:225-30.
    • Balfour HH, Groth KE, Edelman CK, Amren DP, Best JM, Banatvala JE. Rubella viraemia and antibody responses after rubella vaccination and reimmunization. Lancet 1981;1078-80.
    • Meegan JM, Evans BK, Hortsmann DM. Use of Enzyme Immunoessays and the Latex Agglutination Test to Measure the Temporal Appearance of Immunoglobulin G and M Antibodies After Natural Infection or Immuninzation with Rubella virus. J Clin Microb 1983;18:745-8.
    • Herrman KL, Available Rubella Serologic Tests. Rev Infect Dis 1985;S1:S108-S12.
    • Thomas HI, Morgan-Capner P, Cradock-Watson JE, Enders G, Best JM, O'Shea S. Slow maturation of IgG1 avidity and persistence of specific IgM in congenital rubelIa: implications for diagnosis and immunopathology. J Med Virol, 1993; 41: 196–200.
    • Sepulveda-Amor J, Valdespino-Gomez JL, Garcia-Garcia Mde L, Bennett J, Islas-Romero R, Echaniz-Aviles G, de Castro JF A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vacinees in school age children. Vaccine 2002; 20: 2790-5.

  • Las estrategias
    • Castillo-Solórzano C, Carrasco P, Tambini G, Reef S, Brana M, de Quadros CA. New Horizons in the Control of Rubella and Prevention of Congenital Rubella Síndrome in the Americas. J Infect Dis 2003;187 (S1):S146-52.
    • Andrus JK, Roses M. Editorial: Elimination of rubella and congenital rubella syndrome in the Americas: another opportunity to address inequities in health. Pan Am J Public Health, 2004; 15(3):145-6.
    • Castillo-Solórzano C, Andrus JK. Rubella Elimination and Improving Health Care for Women. Emerging Infectious Diseases 2004; 10(11):2017-21
    • Schoenbaum SC, Hyde JN, Bartshesky L, Crampton K. Benefit-cost analysis of rubella vaccination policy. N Engl J Med 1976;294:306-10.
    • Farber ME, Finkelstein SN. A cost-benefit analysis of a mandatory premarital rubella-antibody screening program. N Engl J Med 1979;300:856-9.
    • Preblud SR, Serdula MK, Frank JA, Branding-Bennett DA, Hinman AR. Rubella vaccination in the United States: a ten year review. Epidemiol Rev 1980;2:171-94.
    • Rafnar B. Rubella immunization of teenage girls in Iceland and follow-up after severe rubella epidemic. Bull WHO 1982;60:141-6.
    • Stray-Pedersen B. Economic evaluation of different vaccination programmes to prevent congenital rubella. NIPH Ann (Norway) 1982;46:115-9.
    • Golden M, Shapiro GL. Cost-benefit analysis of alternative programs of vaccination against rubella in Israel. Public Health 1984;98:179-90.
    • Schoenbaum SC. Bennefit-Cost Aspects of Rubella Immunization. Rev Infect Dis 1985;7(Suppl. 1):S210-S1.
    • White CC, Koplan JP, Orenstein WA. Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health 1985; 75:739-44.
    • Gudmadottir M. Cost-Effectiveness of Different Strategies for Prevention of Congenital Rubella Infection: A Practical Example from Iceland. Rev Infect Dis 1985;7(S1): S200-9.
    • Orenstein WA, Preblud SR, Bart KJ, Hinman AR. Methods of assessing the impact of congenital rubella infection. Rev Infect Dis 1985; 7(S1):S22-8.
    • Oreinstein WA, Bart KJ, Hinman AR et al. The opportunity and obligation to eliminate rubella from the United States. JAMA 1984; 251:1988-94.
    • Gunasekera DP, Gunasekera PC. Rubella Immunization – Learning from Developing Countries. Lancet 1996, 347: 1694-5.
    • Hinman AR, Hersh BS, y de Quadros CA. Uso racional de la vacuna contra la rubéola para prevenir las anomalías congénitas por rubéola en las Américas. Rev Panam Salud Pública, 1998, 4:156-160.
    • Cheffins T, Chan A, Keane RJ, Haan EA, Hall R. The impact of rubella immunisation on the incidence of rubella, congenital rubella syndrome and rubella-related terminations of pregnancy in South Australia. Br J Obstetr Gyn 1998;105:998-1004.
    • Panagiotopoulos T, Antoniadou I, Valassi-Adam E. Increase in congenital rubella occurrence after immunization in Greece: retrospective survey and systematic review. BMJ 1999;319:1462-5.
    • Irons B, Lewis MJ, Dahl-Regis M, Castillo-Solórzano C, Carrasco PA, de Quadros CA. Strategies to Eradicate Rubella in the English-Speaking Caribbean. Am J Public Health 2000;90:1545-9.
    • Cutts FT, Vynnycky E. Modelling the incidence of congenital rubella syndrome in developing countries. Int J Epidemiol 1999; 28:1176-84.
    • Centers for Disease Control and Prevention: Nationwide Campaign for Vaccination of Adults Against Rubella and Measles Costa Rica 2001. MMWR Morb Mort Wkly Rep 2001; 150(44):976-9.
    • Castillo-Solórzano, de Quadros CE. Control acelerado de la rubéola y prevención del síndrome de rubéola congénita en las Américas. Pan Am J Public Health 2002;11:273-6.
    • Morice A, Carvajal X, León M, Machado M, Badilla, Reef S, Lievano F, Depetris A, Castillo-Solórzano C. Acelerated Rubella Control and CRS prevention Strengthens Measles Erradication: The Costa Rican Experience. J Infect Dis 2003;187(S1):S158-S163.
    • Kelly H, Worth L, Karapanagiotidis T, Riddell M. Interruption of rubella virus transmission in Australia may require vaccination of adults males: evidence from a Victorian sero-survey. Commun Dis Intel 2004;28:69-73.
    • Zhou F, Reef S, Massoudi M, Papania MJ, Yusuf HR, Bardenheier B, Zimmerman L, McCauley MM. An Economic Analysis of the Current Universal 2-Dose Measles-Mumps-Rubella Vaccination Program in the United States. JID 2004;189(S1):S131-S145.
    • Zhou Fangjun, Reef S, Massoudi M, Papania MJ, Hussain RY, Bardenheier B et al. An Economic Analysis of the Current Universal 2 Dose Measles-Mumps- Rubella Vaccination Program in the United States. J Infect Dis 2004;189:S131-45.

© 2008, Derechos Reservados